Maze Therapeutics, Inc. MAZE 深 滬
已收盤 02-06 16:00:00 美东时间
45.03
+1.080
+2.46%
華盛通- 最 高46.18
- 今 開44.29
- 成交量 66.35万股
- 最 低 42.79
- 昨 收 43.95
- 總市值 21.67亿
- 52周最高 49.25
- 市盈率 靜 578.79
- 換手率 1.38%
- 52周最低 6.71
- 委 比 57.89%
- 總股本 4811.94万
- 歷史最高 49.25
- 量 比 0.94
- 振 幅 7.71%
- 歷史最低 6.71
- 每 手 1
- 風險率 12.18%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在上涨空间31.6%！巴克莱上调台积电目标价至450美元；第一地平线全国银行获5家机构上调目标价
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从77美元升至88美元；摩根士丹利：维持DraftKings"超配"评级，目标价从50美元升至53美元
01-20 10:26
BTIG Maintains Buy on Maze Therapeutics, Raises Price Target to $46
BTIG analyst Julian Harrison maintains Maze Therapeutics (NASDAQ:MAZE) with a Buy and raises the price target from $37 to $46.
01-17 01:24
年终盘点 | 7倍涨幅！2025美股新股王诞生！存储芯片巨头SanDisk升逾585%仅排第二
2025最意外的美股IPO黑马！供应链金融公司Diginex暴涨超7倍登顶，存储芯片巨头SanDisk升逾585%仅排第二，今年最大IPO Medline涨超44%>>
2025-12-31 13:41
美股大行评级 | 潜在涨幅218.88%！Kyverna Therapeutics获摩根士丹利升目标价至25美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持Kyverna Therapeutics"超配"评级，目标价从20美元升至25美元；Maxim Group：维持Capricor Therapeutics"买入"评级，目标价从25美元升至50美元
2025-12-05 08:35
美股大行评级 | 美鹰服饰、CrowdStrike、迈威尔科技获多家机构上调目标价；ACHC、GitLab、Okta遭多家机构下调目标价
今日重点评级关注：Guggenheim：维持Cybin Inc. Common Shares"买入"评级，目标价从39美元升至48美元；HC Wainwright & Co.：维持Capricor Therapeutics"买入"评级，目标价从24美元升至60美元
2025-12-04 09:38
HC Wainwright & Co. Maintains Buy on Maze Therapeutics, Raises Price Target to $60
HC Wainwright & Co. analyst Ananda Ghosh maintains Maze Therapeutics (NASDAQ:MAZE) with a Buy and raises the price target from $50 to $60.
2025-12-04 03:18
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 10:22
Maze Therapeutics To Present Data From Phase 1 Clinical Study Of MZE782 At American Society Of Nephrology
Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced seven presentations at the
2025-11-06 20:14
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
South San Francisco-based Maze Therapeutics has appointed Hervé Hoppenot as Chairman of its Board of Directors, succeeding Charles Homcy, M.D. Hoppenot brings over three decades of experience in biotech, having previously led Incyte Corporation to significant growth. Maze, focused on developing precision medicines for kidney and metabolic diseases, highlighted its promising first-in-human data for MZE782, a recent $150 million private placement, ...
2025-10-06 11:00
